Isis Pharmaceuticals and Eyetech Pharmaceuticals, Jefferson Medical College and the Kimmel Cancer Center, and Molecula

Jun 25, 2004

Premium

Isis Receives Macugen-Related Milestone Payment from Eyetech

Isis Pharmaceuticals said this week that it has received a $1 million milestone payment from Eyetech Pharmaceuticals in connection with Eyetech’s filing of a new drug application with US regulators for the age-related macular degeneration treatment Macugen.

Although Macugen is not an antisense agent, Eyetech licensed certain patents from Isis needed to develop, manufacture, and commercialize the drug, according to Isis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Main menu